Copenhagen, 13 August 2009 - NeuroSearch (NEUR) announces that today 345,238
new shares of DKK 20 nominal value each, corresponding to a total nominal
capital increase of DKK 6,904,760, have been issued. The new shares have been
registered with the Danish Commerce and Companies Agency. As announced in
announcement no. 31-09 from 4 August 2009, all the new shares have been
subscribed by GlaxoSmithKline (GSK) at a market price of DKK 107.84 per share
of DKK 20 nominal value each.

The net proceeds to NeuroSearch from the directed offering to GSK amount to DKK
37.2 million.

The 345,238 new shares have been issued without pre-emption rights for the
company's current shareholders. The issue has been decided by the Board of
Directors in NeuroSearch on the basis of Article 5 of the company's Articles of
Association authorising the Board of Directors to increase the share capital of
the company. The new shares will rank pari passu with and have the same rights
as the existing shares in the company.

Following registration of the new shares, NeuroSearch's share capital amounts
to DKK 332,385,360 (16,619,268 shares of DKK 20 nominal value each).

As of today, the new shares have been admitted to trading and official listing
on NASDAQ OMX Copenhagen under the ISIN of NeuroSearch's existing shares (ISIN
DK0010224666).


Flemming Pedersen
CEO


Contact persons:
Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103


About NeuroSearch
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Eli Lilly and Company and GlaxoSmithKline (GSK), and a
license collaboration with Abbott. The drug pipeline comprises seven clinical
(Phase I-III) development programmes: Pridopidine (ACR16) for Huntington's
disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for
ADHD (Phase II) in partnership with Abbott, ACR325 for the treatment of
dyskinesias in Parkinson's disease (Phase II ready), ACR343 for schizophrenia
(Phase II ready), ABT-560 for the treatment of cognitive dysfunctions (Phase I)
in partnership with Abbott and NSD-788 for anxiety (Phase I). In addition,
NeuroSearch has a broad portfolio of preclinical drug candidates and holds
equity interests in several biotech companies.

fonds.33-09 - gsk closing - uk - final.pdf